Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of duchenne muscular dystrophy

Clinical Nutrition

Volumn 32, Issue 1, 2013, Pages 104-111

  Gordon, Bradley S ^a   Delgado Díaz, Diana C ^a,b   Kostek, Matthew C ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

Author keywords

Inflammation; PGC 1 ; Resveratrol; Utrophin

Indexed keywords

CD45 ANTIGEN; INTERLEUKIN 6; MEMBRANE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN F4 80; RESVERATROL; SIRTUIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UTROPHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERLEUKIN 6 GENE; MALE; MOUSE; MYOSITIS; NONHUMAN; PGC 1ALPHA GENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIBIALIS ANTERIOR MUSCLE; TNF ALPHA GENE; TREATMENT DURATION; UTROPHIN GENE; WESTERN BLOTTING; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; INFLAMMATION MEDIATORS; LEUKOCYTES; MACROPHAGES; MALE; MICE; MICE, INBRED MDX; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; RNA, MESSENGER; SIRTUIN 1; STILBENES; TRANS-ACTIVATORS; UP-REGULATION; UTROPHIN;

EID: 84872610324     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2012.06.003     Document Type: Article

References (39)

1. Hoffman E.P., Brown R.H., Kunkel L.M. Dystrophin - the protein product of the duchenne muscular-dystrophy locus. Cell 1987, 51:919-928.
2. Deconinck N., Dan B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 2007, 36:1-7.
3. Campbell K. Three muscular dystrophies; loss of cytoskeleton-extracellular matrix linkage. Cell 1995, 80:675-679.
4. Tidball J.G., Wehling-Henricks M. Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. Curr Opin Rheumatol 2005, 17:707-713.
5. Tidball J.G., Wehling-Henricks M. Evolving therapeutic strategies for duchenne muscular dystrophy: targeting downstream events. Pediatr Res 2004, 56:831-841.
6. Bushby K., Finkel R., Birnkrant D.J., Case L.E., Clemens P.R., Cripe L., et al. Diagnosis and management of duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010, 9:77-93.
7. Collins C.A., Morgan J.E. Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies. Int J Exp Pathol 2003, 84:165-172.
8. Partridge T. Animal-models of muscular dystrophy - what can they teach us. Neuropathol Appl Neurobiol 1991, 17:353-363.
9. Villalta S.A., Nguyen H.X., Deng B., Gotoh T., Tidball J.G. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 2009, 18:482-496.
10. Bhatnagar S., Kumar A. Therapeutic targeting of signaling pathways in muscular dystrophy. J Mol Med (Berl) 2010, 88:155-166.
11. Handschin C., Kobayashi Y.M., Chin S., Seale P., Campbell K.P., Spiegelman B.M. PGC-1 alpha regulates the neuromuscular junction program and ameliorates duchenne muscular dystrophy. Genes Dev 2007, 21:770-783.
12. Lin J., Wu H., Tarr P.T., Zhang C.Y., Wu Z.D., Boss O., et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002, 418:797-801.
13. Michel R.N., Chin E.R., Chakkalakal J.V., Eibl J.K., Jasmin B.J. Ca2+/calmodulin-based signalling in the regulation of the muscle fibre phenotype and its therapeutic potential via modulation of utrophin A and myostatin expression. Appl Physiol Nutr Metab 2007, 32:921-929.
14. Selsby J.T.M.K., Pendrak K., Barton E.R., Sweeney H.L. Rescue of dystrophic skeletal muscle by PGC-1 alpha involves a fast to slow fiber type shift in the mdx mouse. Plos One 2012.
15. Chakkalakal J.V., Michel S.A., Chin E.R., Michel R.N., Jasmin B.J. Targeted inhibition of Ca2+/calmodulin signaling exacerbates the dystrophic phenotype in mdx mouse muscle. Hum Mol Genet 2006, 15:1423-1435.
16. Guevel L., Lavoie J.R., Perez-Iratxeta C., Rouger K., Dubreil L., Feron M., et al. Quantitative proteomic analysis of dystrophic dog muscle. J Proteome Res 2011, 10:2465-2478.
17. Squire S., Raymackers J.M., Vandebrouck C., Potter A., Tinsley J., Fisher R., et al. Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. Hum Mol Genet 2002, 11:3333-3344.
18. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha. Cell 2006, 127:1109-1122.
19. Elmali N., Esenkaya I., Karadag N., Tas F. Effects of resveratrol on skeletal muscle in ischemia-reperfusion injury. Ulus Travma Acil Cerrahi Derg 2007, 13:274-280.
20. Murase T., Haramizu S., Ota N., Hase T. Suppression of the aging-associated decline in physical performance by a combination of resveratrol intake and habitual exercise in senescence-accelerated mice. Biogerontology 2009, 10:423-434.
21. Jackson J.R., Ryan M.J., Alway S.E. Long-term supplementation with resveratrol alleviates oxidative stress but does not attenuate sarcopenia in aged mice. J Gerontol A Biol Sci Med Sci 2011, 751-764.
22. Moorwood C., Lozynska O., Suri N., Napper A.D., Diamond S.L., Khurana T.S. Drug discovery for duchenne muscular dystrophy via utrophin promoter activation screening. PLoS One 2011, 6.
23. Hori Y.S.K.A., Hosoda R., Tanno M., Miura T., Shimamoto K., Horio Y. Resveratrol ameliorates muscular pathology in the dystrophin mdx mouse, a model for duchenne muscular dystrophy. J Pharmacol Exp Ther 2011, 338:784-794.
24. Zhang Z.Y., Lowry S.F., Guarente L., Haimovich B. Roles of SIRT1 in the acute and restorative phases following induction of inflammation. J Biol Chem 2010, 285:41391-41401.
25. Regnault T.R.H., Zhao L., Chiu J.S.S., Gottheil S.K., Foran A., Yee S.P. Peroxisome proliferator-activated receptor -beta/delta, -gamma agonists and resveratrol modulate hypoxia induced changes in nuclear receptor activators of muscle oxidative metabolism 2010, Ppar Research.
26. Laing X., Ajmo J.M., Rogers C.Q., You M. Resveratrol alleviates alcoholic fatty liver in mice. Alcoholism-clinical Exp Res 2009, 33:161A.
27. Planavila A., Iglesias R., Giralt M., Villarroya F. Sirt1 acts in association with PPAR alpha to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res 2010, 90:276-284.
28. Delgado-Diaz D.C., Gordon B.S., Dompier T., Burgess S., Dumke C., Mazoue C., et al. Therapeutic ultrasound affects IGF-1 splice variant expression in human skeletal muscle. Am J Sports Med 2011, 39:2233-2241.
29. Bradford M.M. A rapid and sensititive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
30. Spencer M.J., Montecino-Rodriguez E., Dorshkind K., Tidball J.G. Helper (CD4(+)) and cytotoxic (CD8(+))T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol 2001, 98:235-243.
31. Evans N.P.M.S., Robertson J.L., Bassaganya-Riera J., Grange R.W. Immune mediated mechanisms potentially regulate the disease time course of duchenne muscular dystrophy and provide targets for therapeutic intervention. PMR 2009, 1:755-768.
32. Wehling M., Spencer M.J., Tidball J.G. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 2001, 155:123-131.
33. Rafael J.A., Tinsley J.M., Potter A.C., Deconinck A.E., Davies K.E. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat Genet 1998, 19:79-82.
34. Wright D.C., Han D.H., Garcia-Roves P.M., Geiger P.C., Jones T.E., Holloszy J.O. Exercise-induced mitochondrial biogenesis begins before the increase in muscle PGC-1 alpha expression. J Biol Chem 2007, 282:194-199.
35. Miura P.T.J., Chakkalakal J.V., Holcik M., Jasmin B.J. The utrophin a 5' untranslated region confers internal ribosome entry site mediated translational control during regeneration of skeletal muscle fibers. J Biol Chem 2005, 280:32997-33005.
36. Khurana T.S.W.S., Chafey P., Chelly J., Torne F.M., Fardeau M., Kaplan J.C., et al. Immunolocalization and developmental expression of dystrohin related protein in skeletal muscle. Neurmuscul Disord 1991, 1:185-194.
37. Chang J.H., Lin K.H., Shih C.H., Chang Y.J., Chi H.C., Chen S.L. Myogenic basic helix-loop-helix proteins regulate the expression of peroxisomal proliferator activated receptor-gamma coactivator-1 alpha. Endocrinology 2006, 147:3093-3106.
38. Fujimori K., Itoh Y., Yamamoto K., Miyagoe-Suzuki Y., Yuasa K., Yoshizaki K., et al. Interleukin 6 induces overexpression of the sarcolemmal utrophin in neonatal mdx skeletal muscle. Hum Gene Ther 2002, 13:509-518.
39. Pedersen B.K. IL-6 signalling in exercise and disease. Biochem Soc Trans 2007, 35:1295-1297.